I want to be sure you know about an important development that all of your contributions to the Alzheimer’s Association have helped make possible.

As you well know, for decades millions of Americans and their loved ones have waited for a new, more effective treatment for Alzheimer’s disease to be available. On November 6, a Food and Drug Administration (FDA) Advisory Committee is meeting to review clinical trial data for a new drug developed for treating cognitive and functional decline in early Alzheimer’s disease.

Given the devastating toll of this disease and the publicly released research data, the Alzheimer’s Association has submitted a statement supporting approval to the FDA Advisory Committee, which will make its recommendation to the FDA.

Whatever the final decision by the FDA, this is an important moment. We have never before been this close to approval of a drug for Alzheimer’s that could change the progression of the disease, not just the symptoms.

You can rightly be proud of what you’ve done to advance the Alzheimer’s Association’s world leading research program — we have played a critical role in every major advancement in the field. I am personally grateful to you for your relentless dedication to our work toward a world without Alzheimer’s and all other dementia.

Without you, none of this happens.

I look forward to sharing more news with you about this as it develops. As always, thank you for everything you do to advance our mission to make a difference today and tomorrow for all of our constituents.

——

Harry Johns
Chief Executive Officer
Alz.org